Our studies presented herein provide a strong rationale for the use of AR or BET inhibitors in COVID-19 treatment to decrease TMPRSS2 and ACE2 expression, and the results of the many clinical studies mentioned above are eagerly awaited. The gene discussed is TMPRSS2; the disease is COVID-19.